Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.

Abstract: The present invention concerns an improved process for the preparation of asymmetric cyclic ureas as well as intermediates in the preparation of asymmetric cyclic ureas. In the process, a diamine of formula (I-a) is selectively monoacylated to give an asymmetric monoacylated diamine which can be converted into asymmetric intermediates. The asymmetric intermediates can be further alkylated, cyclized, and/or modified to give compounds which are useful as HIV protease inhibitors for the treatment of HIV infection. The invention allows for scalable preparation of a wide variety of asymmetrical cyclic ureas.

Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.

Abstract: This invention relates generally to crystalline and salt forms of compounds of formula I: 1

Abstract: This invention relates generally to salt forms the compound of formula I: 1

Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.

Abstract: The present invention concerns an improved process for the preparation of asymmetric cyclic ureas as well as intermediates in the preparation of asymmetric cyclic ureas.

Abstract: A process for the preparation of asymmetric cyclic ureas of Formula (VI) starting from the diamine of Formula (I).

Abstract: This invention provides improved synthetic processes for the preparation of hydroxy-protected cyclic urea compounds of Formula (IX), ##STR1## which are useful as intermediates for the preparation of cyclic urea human immunodeficiency virus (HIV) protease inhibitors, from N-protected aminoaldehydes. The processes of the present invention provide high yields, can be conducted on multikilogram scale, and eliminate the need for chromatographic purification of intermediates or final product.

Abstract: A method for the isolation and purification of an imidazole compound, useful as an angiotensin II receptor inhibitor compound or as a key intermediate therefor, from a mixture of it with its regioisomer in a solvent by treament of the mixture with a strong acid to effect selective precipitation of the desired regioisomeric imidazole salt.

Abstract: A method for isolating and purifying an ester functionalized imidazole compound, useful as an angiotensin (II) antagonist or as a key intermediate therefor, from a mixture of it with its regioisomer in a solvent, by treatment with an alkali metal hydroxide to achieve the regioselective hydrolysis of the undesired regioisomeric ester.

Abstract: Benz[b]azepine compounds, pharmaceutical compositions containing them and methods for the treatment of neurological disorders utilizing them.

Abstract: The invention concerns a novel process for the manufacture of various aryloxyaliphatic aldehydes and related arylthio analogues, which are useful as chemical intermediates. The process involves reacting a dihalogenohydroxyalkane of the formula: HO.C(R.sup.2).sub.2.CHX.sub.2 wherein R.sup.2 is alkyl and X is chloro or bromo with a phenol or thiophenol in the presence of base and is applicable to large scale use.

Abstract: The invention concerns a novel process for the stereospecific manufacture of novel hydroxymethyl lactols of the formula I by a one step reduction of a corresponding lactone carboxylic ester of the formula II (many of which esters are novel) using a reducing agent such as diisobutylaluminium hydride at about ambient temperature. The lactols of formula I are intermediates for the production of pharmacologically active 1,3-dioxane alkenoic acids useful in the treatment of certain cardiovascular and pulmonary medical conditions. Certain of the esters of formula II are novel and are also included in the invention.

Abstract: An apparatus for generating trigger signals responsive to a selected pattern of event detection signals, the apparatus comprising an interim function bus, programmable means to selectively energize conductors of the interim function bus on detection of the selected event detection signal pattern, and programmable means to generate the trigger signal on detection of a selected pattern of interim function bus signals. The generating means are programmed for pattern recognition by binary data appearing on control lines from a shift register, the shift register being loaded by serial data from external control circuits. The apparatus also includes provisions for synchronizing the generation of signal patterns on the interim function bus to a system clock, and for synchronizing the generation of trigger signals to clocks associated with triggerable devices.

Abstract: The invention provides a novel process for making novel (4-phenyl-1,3,-dioxan-cis-5-yl)alkenoic acids of the formula I in which Ra and Rb are independently hydrogen, alkenyl, alkyl, halogenoalkyl, pentafluorophenyl, aryl or aryl-(1-4C)alkyl; or Ra and Rb together are polymethylene; Rc is hydroxy or (1-6C)alkanesulphonamido, A is vinylene, n is 1, Y is polymethylene, and benzene ring B bears various optional substituents. The process involves the reaction of an aldehyde of formula II with an ylid to give an erythro-diol of formula III which is then cyclized to the required dioxane derivative of formula I. The invention also provides a novel process for making the aldehydes of formula II from the corresponding lactols of formula IIa, which are themselves obtained with the correct trans-stereochemistry by two selective reductions of a trans-phenylparaconic acid of formula V. The compounds of formula I are useful as therapeutic agents.